


PHARMACEUTICAL 2019

Corvus Pharmaceuticals Inc. Rank 53 of 363







PHARMACEUTICAL 2019



Corvus Pharmaceuticals Inc. Rank 53 of 363

The relative strengths and weaknesses of Corvus Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Corvus Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 104% points. The greatest weakness of Corvus Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 24% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 190% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	115,589
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,027
Liabilities, Non-Current	869
Other Assets	463
Other Compr. Net Income	7.0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,283
Other Revenues	0
Property and Equipment	2,180
Research and Development	38,586
Selling, General and Administrative Expense	10,636

Output Variable	Value in 1000 USD
Assets	118,232
Liabilities	7,896
Expenses	49,222
Revenues	0
Stockholders Equity	110,336
Net Income	-46,939
Comprehensive Net Income	-46,936
Economic Capital Ratio	227%

